Try our mobile app

General information

Country: UNITED STATES

Sector: Drug Manufacturers — General

Categories: @vaccine-makers   

Merck & Co., Inc. is a global health care company that delivers health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products, which it markets directly and through its joint ventures. The Company has operations in pharmaceutical, animal health, and consumer care.
Website: merck.com


  • Good financial results growth rate 26.7% (average between last period year over year growth for revenue and EBITDA), there is acceleration compared to average historical growth rates (9.1%)
  • Dividend yield for the last twelve months 3.1%
  • Free cash flow yield 0.1% (LTM)
  • Share price is 44.9% higher than minimum and 19.9% lower than maximum for the last 3 years
  • The company is undervalued by EV / LTM EBITDA multiple compared to target level (11.1x vs
    )
  • Fundamental value created in LTM (estimate)
  • For the last 3 months insiders sold company shares on $1.3 mln (-0.001% of cap.)

Key Financials (Download financials)

Ticker: MRK
Share price, USD:  (0.0%)106.45
year average price 87.18  


year start price 99.70 2024-12-27

min close price 73.47 2025-05-14

max close price 106.45 2025-12-24

current price 106.45 2025-12-26
Common stocks: 2 528 810 012

Dividend Yield:  3.1%
FCF Yield LTM: 0.1%
EV / LTM EBITDA: 11.1x
EV / EBITDA annualized: 9.3x
Last revenue growth (y/y):  +3.7%
Last growth of EBITDA (y/y):  +49.7%
Historical revenue growth:  +3.0%
Historical growth of EBITDA:  +15.2%
Target EV / EBITDA (hist percentile):
Express share price potential:
Fundamental value created in LTM:
EV / LTM EBITDA mutiple calculation
Market Cap ($m): 269 192
Net Debt ($m): 23 217
EV (Enterprise Value): 292 409
EBITDA LTM ($m): 26 386
EV / LTM EBITDA: 11.1x
Price to Book: 5.2x

Revenue and EBITDA

Quarterly values ($m)

Change (y/y)

Cash Flow

FCF ($m)

Net Debt / Cash and Equivalents ($m)

Share price and dividends (Download history)

Share price

Payment USD per share

Multiple and potential

EV / EBITDA

Potential dynamics

News


2025-12-24zacks.com

Why Merck (MRK) Outpaced the Stock Market Today

2025-12-19zacks.com

Can Merck Successfully Steer Through the Upcoming Headwinds?

2025-12-19zacks.com

Here's Why Merck (MRK) is a Strong Growth Stock

2025-12-18seekingalpha.com

Merck's Deep Pipeline And Cash Flow Strength Support The Bull Case

2025-12-18zacks.com

Merck (MRK) Rises Higher Than Market: Key Facts

2025-12-17reuters.com

Exclusive: US FDA taps Merck drugs with blockbuster sales potential for national priority vouchers

2025-12-17businesswire.com

KEYTRUDA® (pembrolizumab) Plus Padcev® (enfortumab vedotin-ejfv) Significantly Improved Event-Free Survival, Overall Survival and Pathologic Complete Response Rates for Cisplatin-Eligible Patients with MIBC When Given Before and After Surgery

2025-12-15zacks.com

MRK Gets Positive CHMP Opinion for Expanded Use of Winrevair in PAH

2025-12-12businesswire.com

Merck Receives Positive EU CHMP Opinion for Expanded Use of WINREVAIR™ (sotatercept) in Adults with Pulmonary Arterial Hypertension (PAH, WHO* Group 1 Pulmonary Hypertension)

2025-12-11zacks.com

Merck (MRK) Laps the Stock Market: Here's Why
More information for subscribed users:
detailed calculation of
Potential and Created Value,
website traffic data